Annotation Detail
Information
- Associated Genes
- ROS1
- Associated Variants
- ROS1 TFG-ROS1
- Associated Disease
- inflammatory myofibroblastic tumor
- Source Database
- CIViC Evidence
- Description
- Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-ROS1 fusion. CT scans after 3 cycles of crizotinib treatment showed a reduction of the tumor mass which continued to decrease at the time of publication after 4 months of crizonitib treatment.
- Evidence Type
- Predictive
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1444
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4941
- Variant URL
- https://civic.genome.wustl.edu/links/variants/576
- Rating
- 3
- Disease
- Inflammatory Myofibroblastic Tumor
- Evidence Direction
- Supports
- Drug
- Crizotinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24875859
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Crizotinib | Sensitivity | true |